Ruxience Dosage

Generic name: rituximab
Brand names: Riabni, Rituxan, Ruxience, Truxima
Drug class: CD20 monoclonal antibodies

Medically reviewed by  A Ras MD.

 Recommended Adult Dosing

Dosage forms:  INJ

CD20-positive B-Cell non-Hodgkin lymphoma, relapsed or refractory

[monotherapy]

Dose: 375 mg/m^2/dose IV qwk x4wk or x8wk; Info: for pts w/ low-grade or follicular dz; may give additional 4wk tx in pts who progress after initial tx; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts

[ibritumomab tiuxetan combo tx]

Dose: 250 mg/m^2/dose IV x1 on day 1, then on days 7, 8, or 9 of regimen; Info: for pts w/ low-grade or follicular dz; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts

CD20-positive B-Cell non-Hodgkin lymphoma, previously untreated

[follicular type, chemo combo tx]

Dose: 375 mg/m^2/dose IV x1 on day 1 of each cycle; Info: give up to 8 cycles; if complete or partial response achieved, may give maint. monotherapy 375 mg/m^2/dose IV x1 on day 1 of 56-day cycle x12 cycles starting 56 days after completion of 1st-line combo chemo; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts

[follicular type, ibritumomab tiuxetan combo tx]

Dose: 250 mg/m^2/dose IV x1 on day 1, then on days 7, 8, or 9 of regimen; Info: for pts w/ complete or partial response after completion of 1st-line combo chemo; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts

[diffuse large B-cell type, chemo combo tx]

Dose: 375 mg/m^2/dose IV x1 on day 1 of each cycle; Info: give up to 8 cycles; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts

CD20-positive B-Cell non-Hodgkin lymphoma, non-progressing

[375 mg/m^2/dose IV x1 on days 1, 8, 15, 22 of 6-mo cycle]

Start: after completion of 1st-line combo chemo; Info: for pts w/ low-grade dz; give up to 16 doses (4 cycles); give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts

CD20-positive CLL/SLL

[500 mg/m^2/dose IV x1 on day 1 of 28-day cycle, starting cycle 2]

Start: 375 mg/m^2/dose IV x1 on the day before cycle 1; Info: give x6 cycles; part of multi-drug chemo regimen; give HSV and PCP prophylaxis during tx and up to 12mo after D/C; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts

Rheumatoid arthritis, mod-severe

[1000 mg IV q2wk x2 doses]

Info: for pts w/ inadequate response to TNF antagonist; may repeat course q16-24wk; use w/ methotrexate; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts

Granulomatosis w/ polyangiitis (GPA)

[induction tx]

Dose: 375 mg/m^2/dose IV qwk x4wk; Info: use w/ glucocorticoids; give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts

[subsequent tx]

Dose: 500 mg IV q2wk x2 doses, then 500 mg IV q6mo; Start: 16-24wk after last induction tx w/ rituximab, or w/in 4wk of dz control achieved w/ other standard of care immunosuppressants; Info: give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts

Microscopic polyangiitis (MPA)

[induction tx]

Dose: 375 mg/m^2/dose IV qwk x4wk; Info: use w/ glucocorticoids; give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts

[subsequent tx]

Dose: 500 mg IV q2wk x2 doses, then 500 mg IV q6mo; Start: 16-24wk after last induction tx w/ rituximab, or w/in 4wk of dz control achieved w/ other standard of care immunosuppressants; Info: give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts

Renal dosing

[see below]

renal impairment: no adjustment

HD: no adjustment; no supplement; PD: not defined

Hepatic dosing

[not defined]

SRC: NLM .